GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

Biogen

British American Tobacco

Imperial Brands PLC

Lockheed Martin

Altria

Merck

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The February 2021 Heat Map

Eli Lilly

Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.

Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

We see positive long-term outlook for the company benefiting from strong product portfolio and pipeline as well as its market leading position. GSK is cheap relative to its competitors and value should be unlocked from multiples expansion.

GlaxoSmithKline: 30% Undervalued And Spinoff To Drive Growth

GlaxoSmithKline (GSK) has hit some rough patches lately, but some analysts are concerned the nearly $100-billion pharmaceutical giant could be coming off the rails completely.

GlaxoSmithKline Faces a Tough Road Ahead

Gilead Sciences

These are the recently approved treatments biotech investors want to keep their eyes on in 2021.

3 Blockbuster Drug Launches to Watch This Year

Glaxo (GSK) and J&J's (JNJ)get FDA approval for Cabenuva, a once-monthly injectable regimen of cabotegravir and rilpivirine, for the treatment of adults with virally suppressed HIV-1 infection.

Glaxo (GSK) Gets FDA Nod for Long-Acting HIV Regimen Cabenuva

Pfizer

In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration. What Happened: The injectable — Cabenuva — is designed to replace the current treatment of HIV in adults which is based on taking daily pills.

Pfizer, GSK-Backed ViiV First To Get FDA Approval For Injectable Drug To Treat HIV

AbbVie

Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecasts made by industry analysts. This is according to a report from global management consulting firm L.E.K.

AbbVie, Roche, Glaxo Are Experts at Product Launches

Merck KGaA's drug development programme has suffered a setback with the most important clinical trial of its cancer drug hopeful bintrafusp alfa stopped because the treatment does not appear to work.

Merck KGaA, GSK suffer lung cancer drug setback

Vir Biotechnology

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

PARIS, Jan. 11, 2021 /PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based...

Eligo inks deal with GSK potentially worth up to $224M

Bank of New York Mellon

Intel

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Colgate-Palmolive

CVS Health

Henry Schein

Johnson & Johnson

Procter & Gamble

DENTSPLY SIRONA

As the Covid-19 pandemic worsens, the case for dental stocks to buy might not seem too bright. However, this sector is a very broad one, with upside opportunities available right now.

8 Dental Stocks If You Want to Clean Up

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

British pharmaceutical company GlaxoSmithKline PLC's (NYSE: GSK) majority-owned subsidiary ViiV Healthcare received the marketing authorization approval for its HIV treatment in the European Union, the company announced on Monday. What Happened: ViiV announced that the European Commission authorized Vocabria (cabotegravir injection and tablets) to be used in combination with Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen Pharmaceutical's Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets) to treat virologically suppressed adults with an HIV infection.

GlaxoSmithKline's ViiV Healthcare Bags EU Marketing Authorization For Long-Acting HIV Treatment

TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with GlaxoSmithKline ("GSK")[1]. The single-target agreement is focused on the discovery and...

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System

In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day.

GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for an experimental antibody-based COVID-19 treatment. The Phase 3 study is part of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines Program.

Vir, GSK's experimental COVID-19 treatment moves into a Phase 3 clinical trial

LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a...

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US

Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.

Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV

The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.

Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults

Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.

Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate

Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn't work as well in older people. The drugmakers' Friday announcement created a roadblock in its race to produce a safe and effective inoculation for COVID-19 — the same day Health and Human Services Secretary Alex Azar said the.

Sanofi, GlaxoSmithKline delay COVID-19 vaccine rollout to late 2021

Sanofi and GlaxoSmithKline, the French and British pharmaceutical groups, said on Friday that they would delay the launch of their joint coronavirus vaccine until the end of 2021.

Sanofi/GSK vaccine setback adds to uncertainty ahead of Europe's mass inoculation campaigns

News for GlaxoSmithKline Stock (GSK)